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ABSTRACT
Publication in peer-reviewed journals is a key part of advancement in science and a 
vital part of development of the scientific basis for public health practice. The proc-
ess of publication should promote rigorous standards of high quality ethical research 
and the wide dissemination of their findings. When considering the issues arising 
from publication in public health, relevant frameworks include those from the field 
of publication ethics, public health practice and epidemiological research. 
The consequences of poor, or frankly fraudulent science, can have a substantial 
adverse impact both on health, and on the use of resources, and public credibility 
because of the population based nature of public health interventions. Professional 
and scientific journals therefore have a critical role in promoting and preserving the 
highest possible ethical and professional standards to advance the field of public 
health practice.
I present here a personal view of some of these ethical issues, predominantly from 
the perspective of an experienced editor, but also to some extent that of reviewers and 
of course, the authors. 
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INTRODUCTION 
Journal editors make decisions every day about what articles to publish, and 
what to commission. These decisions are strongly influenced by value 
judgments about what they perceive to be important and relevant to their 
field. Where then do ethics come into this? The definition of ethics according 
to the Oxford Dictionaries is “the moral principles that govern a person’s 
behaviour or the conducting of an activity” or the “branch of knowledge that 
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deals with moral principles”.1 In this paper I will consider the first meaning, 
and will address this both from the perspective of the journal editor him or 
herself, and secondly from that of the editor dealing with authors.
RELEVANT ETHICAL FRAMEWORKS
A short overview of existing ethical frameworks from the field of peer 
review publication, public health practice and epidemiological research is 
given below.
Peer-reviewedpublications
The Committee on Publication Ethics (COPE), (an international organisation 
based in the UK) produce comprehensive guidance for editors and publishers 
of peer-reviewed journals. In 2011, they published updated guidance, the 
Code of Conduct and Best Practice Guidelines for Journal Editors.2 A 
summary of the general duties of editors are shown in Table 1.
Table 1 
GeneralDutiesandResponsibilitiesofEditors.
1. Editors should be accountable for everything published in their journals. 
This means the editors should:
2. strive to meet the needs of readers and authors;
3. strive to constantly improve their journal; 
4. have processes in place to assure the quality of the material they publish; 
5. champion freedom of expression; 
6. maintain the integrity of the academic record; 
7. preclude business needs from compromising intellectual and ethical standards; 
8. always be willing to publish corrections, clarifications, retractions and apologies when 
needed.
Source: Code of Conduct and Best Practice Guidelines for Journal Editors. COPE 2011.2
The World Association of Medical Editors (WAME)3 is an international 
nonprofit voluntary association of editors of peer-reviewed medical journals 
from countries throughout the world who seek to foster international 
cooperation among and education of medical journal editors and also issues 
guidelines for good practice. Notably in 2009, the WAME Editorial Policy 
and Publication Ethics Committees issued a statement about conflicts of 
interest in publication in peer-reviewed medical journals.4 
Ethicsofpublication 3
Publichealthpractice
A number of ethical frameworks have been developed to support public 
health professionals and policymakers. A sytematic review by ten Have, et 
al.,5 identified six frameworks: Kass,6 Childress, et al.,7 the Public Health 
Leadership Society,8 all of which focus on public health policy in the United 
States; the Nuffield Council on Bioethics framework,9 which parti cularly 
explores a model of appropriate intervention from the United Kingdom; the 
European Public Health Ethics Network (EUROPHEN) framework,10 which 
concentrates on public health policy in Europe; and Tannahill’s framework,11 
which is directed at the area of public health, health promotion and health 
improvement. Most of them provide a set of values or principles that serve 
as a standard for evaluating policy. Moreover, most frameworks articulate 
both the positive ethical foundations for public health and ethical constraints 
or concerns. 
Epidemiologicalresearch
Coughlin12 summarises existing ethics guidelines for epidemiologists, 
recognizing that epidemiological research produces different ethical issues 
from clinical research, particularly with respect to the communities and 
participants who take part in research. Particular issues he identifies relate 
to: minimizing risks and providing benefits; avoiding and disclosing 
conflicts of interest; obligations to communities; informed consent; privacy 
and confidentiality; and ensuring proposals are subject to appropriate 
ethical review. Other more generic issues in these guidelines relate to 
scientific misconduct, intellectual property and data sharing, publication of 
research findings, and cross-cultural or international health research. These 
complement national guidelines for clinical research issues by organisations 
such as the Medical Research Council in the UK,13 and the National 
Institutes of Health in the US.14
PRESSURES ON EDITORS
Editors are subject to competitive pressures as they want their journal to 
succeed in what are often crowded fields. Depending on the journal, it will 
be run as a commercial venture, often by a large multinational company 
which may have other commercial interests, or as a specialist society 
journal, sponsored by that society and subsidized by membership income. 
Many society journals are supported by not-for-profit publishers. Irrespective 
of the source of funding, editors will want their journal to be successful—
and to be seen as such. 
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MaximisingtheImpactFactor
The overarching metric of success in most contexts is seen to be the Journal 
Impact Factor—this is “a measure of the frequency with which the “average 
article” in a journal has been cited in a particular year or period. The annual 
JournalCitationReports(JCR)impact factor is a ratio between citations 
and recent citable items published.”15 Clearly, this is not the only measure 
of success; reputation, ability to attract high profile authors, high circulation 
figures, appeal and wide dissemination to the target audience (which may 
not be primarily academic), and making a profit are other key factors. 
However, some of these are intrinsically linked to the impact factor as 
explored further below.
The impact factor allows journals to compare their “performance” 
directly with each other. Journals with a high impact factor are considered 
more prestigious, may count more favourably for academics in career terms, 
and will therefore attract more submissions of higher quality. As a result, 
there are considerable pressures on journal editors to develop editorial 
strategies that maximize their impact factor. 
In general terms, relevant, rigorous research of better quality will tend to 
be cited more frequently, and thus editorial strategies that look for quality 
and relevance in the given field will be likely to be cited more frequently, and 
to drive up the impact factor. However, there can also be potential distorting 
factors. Papers that have a large number of references to articles already 
published in their journal (“self-citation”) will also drive up the citation rates. 
Publishing a highly controversial paper can result in high citation levels. 
This was demonstrated when the Lancet published the original paper by 
Andrew Wakefield in 199816 linking measles, mumps and rubella (MMR) 
vaccine, later partially retracted by the Lancet 17 and finally fully retracted 
in 2010.18 This paper, and the subsequent media furore led to a dramatic 
decline in uptake rates in the MMR vaccine in the UK, with vaccination 
rates falling to 80 percent in 2003-2004.19 They are still below the 95 
percent level recommended by the World Health Organization to ensure 
herd immunity, and in 2008, for the first time in 14 years, measles was 
declared endemic in England and Wales. Subsequent investigation by the 
BMJ and investigative journalist Brian Deer20 demonstrated that Andrew 
Wakefield was guilty of falsification of data; not one of the 12 cases reported 
in the 1998 Lancet paper was free of misrepresentation or undisclosed 
alteration, and in no single case could the medical records be fully 
reconciled with the descriptions, diagnoses, or histories published in the 
journal. After a 217 day hearing by the UK General Medical Council 
(GMC), it was concluded that he was guilty of dishonesty concerning the 
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study’s admissions criteria, its funding by the Legal Aid Board, and his 
statements about it afterwards and his name was erased from the medical 
register.21 However, the co-authors in this study did not escape without 
blame. Despite the clear finding of the GMC panel that it was Wakefield 
alone who wrote the final version of the paper, with his coauthors being 
unaware of which child was which in the paper’s patient anonymised text 
and tables, they clearly failed in their duties as authors. The Lancet did not 
escape unscathed either, with many believing the journal should have 
retracted the paper much earlier. 
Conversely, some important articles may not appear to have significant 
potential for citation. Public health issues of importance in low and middle 
income countries may not immediately be attractive to editors, due to the 
lack of potential for citation—there are fewer authors in those countries who 
are publishing, and therefore likely to cite the articles. Research done in 
relatively small countries newly acceded to the European Union may struggle 
to find an audience. Many journal editors are keen to support young doctors, 
graduates from master’s programmes or those training in the public health 
professions to publish in journals, but may be concerned about the effect of 
these (usually small research projects) on the journals profile. To escape the 
dominance of high income country publications, it may be necessary to 
establish specialist journals in lower and middle income countries.
A particular dilemma occurs when a submission is in an important area 
in public health terms, but may have a relatively weak design, or low response 
rate, and a judgment has to be made as to whether this still constitutes a 
relevant contribution to the field—this can be the case in the area of public 
health interventions, where field work is challenging. One example might be 
where a survey has a response rate that is low in conventional terms but is 
addressing an important health issue, such as a study of second hand exposure 
to tobacco in casino workers that dem onstrated respiratory symptoms in 84 
percent of those surveyed,22 appreciably higher than that reported in studies 
of bar workers, and contributed to the policy debate as to whether this high 
risk group of workers should be excluded from tobacco-free legislation. 
In contrast, there may be perfectly designed epidemiological studies 
that are scientifically robust, but add little to our understanding of how to 
improve public health, or where findings are statistically significant, but 
appear to have little public health impact or relevance. Judging if these 
warrant publication can be challenging. 
Increasingly important is the consideration of external validity, part-
icularly important in more applied fields of research such as public health, 
where we are particularly interested in knowing if programmes effective in 
one situation will work in other settings or with other populations. Steckler, 
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et al.23 have highlighted the role that journal editors can play, not only in 
promoting high standards of reporting of characteristics relating primarily 
to the internal validity of research such as the Consolidated Standards of 
Reporting Trials (CONSORT) Statement24 for randomised controlled trials, 
and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement for sytematic reviews,25 but also for external 
validity, by ensuring that authors include key details pertaining to these 
issue. These are shown in Table 2.
Table 2
ReportinginformationrequiredtoconsiderExternalValidityofstudies
1. Study participant recruitment and selection procedures, participation rates, and 
representative nature at the levels of individuals, intervention staff, and delivery settings.
2. Level and consistency of implementation across program components, settings, staff, 
and time.
3. Impact on a variety of outcomes, especially those important to populations, practitioners, 
and decision makers (e.g., quality of life, program costs, and adverse consequences).
4. Follow-up reports should include attrition at all levels in item 1, long-term effects on 
outcomes in item 3, and program sustainability, modification, or discontinuance.
Source: Steckler, et al. 2008.23
Negativefindings
A particular challenge relates to those studies which demonstrate negative 
findings—important but “boring”—less likely to excite their audience, and 
less likely to attract large number of citations but critically important. 
Evidence suggests that authors are less likely to write up negative research 
findings and submit them for publication, and even when they do so, they 
take longer to be published and are more likely to be published in low 
impact or more difficult to access journals.26 Early hypothesis-generating 
research may be given a high profile and much publicity, later refuted by 
more robust epidemiological research that receives little attention from the 
media or the profession. A classic example is that of vitamin K injections, 
where case-control studies in the 1990s suggested a possible link between 
vitamin K injections and childhood leukaemia. This was followed by 
studies in the UK, across Europe, and in the US, which found no association. 
However, the controversy caused public concern about a highly effective 
intervention to prevent vitamin K deficiency bleeding (VKDB) in babies.27 
The role of the editors in accepting papers that identify potential (but 
unproven) public health risks and harms versus the potential damage and 
loss of confidence in effective interventions can be a difficult balance.
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A further example of a publication of a paper that fell into the category 
of important but dull—and that was potentially considered “too unsurprising, 
or too radical in its threat to established interests or, paradoxically, both”28 
was a paper which modeled the effectiveness of screening for future 
cardiovascular disease using age alone compared to multiple risk factors and 
age.29 This paper concluded, counterintuitively, that simply using age was as 
effective as more complicated screening methods using serum cholesterol 
and blood pressure. Smith28 describes how the publication of this paper took 
over two years, required 24 different reviewers, and yet concludes that 
although the final version that was ultimately published is different, the 
central message—that age alone is as good as complex risk assessment was 
fundamentally unchanged. Smith urges us to consider if we should “scrap” 
pre-publication review and concentrate instead on post-publication review. 
Parochialism
Another tension can relate to the audience for the journal; how parochial 
should a journal be? If the main focus is for example on UK public health 
practice will including more international articles alienate the core audience? 
This may be a concern in perpetuating a north-south divide in the publishing 
literature which then exacerbates the already significant gap in funding for 
research between the developed and developing world. This has been termed 
the “10/90 gap” by the Global Forum for Health Research30 based on data 
which shows that there is a gross imbalance between the funding for health 
research applied to the health problems of low and middle income countries 
and the burden of preventable disease found there. Public health is clearly a 
global discipline, and we must learn to take evidence derived in one setting 
and apply it to others. However, evidence may be interpreted differently—
or extra weight given—as is evident in the differing policies regarding folic 
acid food fortification of food in the US and Europe. Folic acid food 
fortification has been mandatory in the US since 1996 and has been 
associated with a 25 percent reduction in neural tube defects,31 in Canada 
since 1998 and recommended and subsequently in over 60 countries —but 
still not implemented in the UK since 2009, nor yet in any European country, 
except Kazakhstan.
ConflictsofInterest
Other key issues with respect to journals relate to advertising and sponsorship 
and the potential for this to distort editorial decision-making. Although in 
general the potential for commercial sponsorship in the world of public 
health journals is much more limited as compared to major medical journals, 
particularly with respect to pharmaceutical products, it remains a concern. 
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The recent exposé published in the BMJ32 examining the growth of 
sports drinks, graphically outlined the interdependency of commercial 
sponsorship, sports medicine journals, academics and editorial committee 
membership that together promoted the belief that sports drinks were 
essential for essential hydration in any sort of physical activity. Another area 
of public health practice where there has been considerable concern that 
commercial interests have had an undue influence is pandemic influenza. As 
outlined by Cohen,33 decisions made within the WHO led to national 
governments committing funds equivalent to millions of British Pounds to 
buy anti-virals and vaccines during the 2009 H1N1 influenza pandemic. 
WHO has conceded that the arrangements they have include effective 
mechanisms to deal with conflicts of interest.34 However, Evans35 concludes 
that whilst some have proposed that the pharmaceutical industry manipulated 
a fake pandemic, the real issue is a lack of processes for dealing with conflict 
of interest. Undoubtedly, issues of selective publication have played a key 
part in the evidence base for the anti-viral drug oseltamivir (Tamiflu®); an 
updated CochraneReview36 has concluded that it is not possible to draw 
conclusions about its effect on complications or transmission as full clinical 
study reports are unavailable to them.
A particular concern in the field of public health has been the pernicious 
influence of the tobacco industry in sponsoring, frequently covertly, 
research which has aimed to confuse or obfuscate key findings linking 
second hand exposure to tobacco to adverse impacts on health.37 This raises 
issues about how explicit conflicts of interest are, and in particular whether 
journals should have a blanket policy to not accept any articles from sources 
with any connection to the tobacco industry. Whilst some journals have a 
set policy of not accepting articles from certain sources, others consider 
each case on its merit, and require full disclosure of any commercial links, 
although policing this is difficult. However, editors always need to be aware 
of potential bias arising from conflicts of interest from funders; this can 
arise not only from those with a commercial interest such as pharmaceutical, 
food and beverage companies, but also from government or non-govern-
mental organisations keen to prove by evaluative research that their 
interventions or policies are cost-effective.
 One area that has proved challenging to a number of journal editors is 
where the organization hosting the journal has other commercial interests 
that are seen to be in direct ethical opposition to those espoused by the 
journal. This direct contradiction was illustrated by the global company 
Reed Elsevier, which publishes many medical and public health journals, 
including the Lancet, and at the same time was also promoting arms sales 
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across the world.38 This led to a campaign39 by academics and doctors for 
Reed Elsevier to divest themselves of this part of their business, which they 
duly did in 2007. However, there is now a new movement and campaign, 
focused particularly on Elsevier, that is calling for a boycott of the company 
because of its business practices. There is concern that commercial pub-
lishers make profits based on the free labour of academics and subscription 
fees from their institutions’ libraries, for a service that has become largely 
unnecessary, and that they actively support measures that limit the free 
transfer of information and research findings.40 
The rise of open access publishing is in part underpinned by an ethical 
belief that research is a public good and an increasing number of influential 
research funders now require that there should be unrestricted access to the 
published output of research. In addition, a number of publishers, make 
their journals free to those in selected low income countries, promoting 
dissemination to those who might not otherwise afford them. 
In his book, TheTroublewithMedicalJournals,41 Richard Smith, the 
former editor of the BMJ, explored the issues of conflicts of interest in 
depth, and highlights the complex links and ties between major medical 
journals and the pharmaceutical industry, and how these can work together 
against the public interest.
Table 3
EssentialTensionsinJournalEditing
 Ensuring a balance between:
• Underrepresented topics and timely results. 
• Coherent theme and diversity of topics. 
• Practice and research. 
• Historical and current content. 
• Social science and biomedical science. 
• Debate and evidence. 
• External and internal funding. 
• Commissioned and unsolicited contributions. 
• Editorial review and peer review. 
• Images and text. 
Source: Northridge, et al. 2004.43
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EditorialFreedom
The counterside to conflicts of interest is the notion of editorial freedom; as 
outlined by WAME4: “Editors-in-chief should have full authority over the 
editorial content of the journal, generally referred to as “editorial inde-
pendence.” Owners should not interfere in the evaluation, selection, or 
editing of individual articles, either directly or by creating an environment 
in which editorial decisions are strongly influenced.” The need to reaffirm 
this independence, and to maintain a clear line of separation between the 
journal and its owner—in this case a professional association, was 
eloquently made by Northridge, et al.42 with respect to the American
JournalofPublicHealth in 2005. In an earlier article Northridge, McLeroy 
and Haviland43 coherently described a list of ten essential tensions in editing 
a journal, including the need to balance under-represented topics, with 
coherence and scientific quality and engendering critical debate (Table 3)
Peerreviewers
Peer reviewers are a fundamental part of the system, yet this work is generally 
unremunerated and unrecognized. It can be difficult to identify reviewers 
who are willing to give the considerable time and energy needed for critiquing 
and usually improving submitted papers. Journals endeavor to recognize 
reviewers though the publication of reviewers, letters of thanks and other 
gestures, but ultimately are very dependent on people’s willingness to give 
their time and to contribute to what they see as a public good or professional 
duty. Another dilemma can relate to the choice of peer reviewers. Should you 
select those recommended by the authors? Or others? Should peer review be 
anonymous or would it be better to know who provided feedback?
Will those working in a similar field be well placed to review an article 
or more likely to be highly critical as they are potentially direct competitors? 
A number of editors have attempted to improve the consistency and quality 
of peer review by developing detailed guidance aimed at those undertaking 
this activity.44-46
AuthorshipandPlagiarism
Editors need to be aware that the pressures to publish on academics are 
pervasive. Ensuring that all authors have contributed to the work, and are 
able to defend authorship is done through submission processes that require 
statements to be made and signed on these issues, but to some extent editors 
have to take at face value these declarations. Another area where editors can 
get drawn into disputes is where the authors cannot agree on authorship, or 
disagree about the order, or inclusion of one of more. In general these are 
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referred back to the authors to resolve. The Committee on Publication Ethics 
COPE2 is a forum for editors and publishers of peer-reviewed journals to 
discuss all aspects of publication ethics and provides useful advice in these 
cases. 
Plagiarism is when somebody presents the work of others (data, words 
or theories) as if they were his/her own and without proper acknowledgment. 
This can result in authors submitting similar papers to journals at the same 
time, or submitting minor variants of work to different journals.47 Although 
these types of issues are becoming easier to detect with the search facilities 
of the World Wide Web, they can be very difficult to detect, and often depend 
on the thoroughness of reviewers and editors, together with a modest index 
of suspicion. Examples of plagiarism given by COPE include individuals 
plagiarising others work (both published and unpublished from doctoral 
theses), submitting duplicate publications (self plagiarism), and plagiarising 
reviewer’s work.
Researchmisconduct
The area of research misconduct is extremely difficult and requires close 
work between institutions and editors who may suspect misconduct. The 
potential damage from research misconduct has already been highlighted by 
the case of Andrew Wakefield. Detecting misconduct demands vigilance, and 
acting on concerns requires collaboration between both institutions and 
editors, both of whom have potentially much to lose. Different countries have 
different arrangements to deal with research misconduct and there is a call 
for UK research funders and others to do more to tackle research misconduct.48 
However, editors have a key role to play as outlined by COPE (Table 4).
Table 4
Dutiesrelatingtoresearchandpublicationmisconductforeditors
Publish the contact details of their editor-in-chief who should act as the point of contact for 
questions relating to research and publication integrity;
Inform institutions if they suspect misconduct by their researchers, and provide evidence to 
support these concerns;
Cooperate with investigations and respond to institutions’ questions about misconduct 
allegations;
Be prepared to issue retractions or corrections (according to the COPE guidelines on 
retractions) when provided with findings of misconduct arising from investigations;





Editing a peer-reviewed public health journal is an enormous privilege. It 
brings with it ethical responsibilities and challenges, some of which have 
been highlighted in this article. Publication in peer-reviewed journals 
remains a key method for establishing and progressing the evidence base 
for public health practice and providing tools for policy development and 
implementation. Editors must remain vigilant to avoid allowing external 
drivers to distort their decision making processes and continue to strive to 
maintain integrity and high scientific standards. 
Acronyms List:
COPE = Committee on Publication Ethics
GMC = UK General Medical Council
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WAME = World Association of Medical Editors
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